甲状腺癌
甲状腺癌是一种起源于甲状腺的恶性肿瘤,甲状腺位于颈部底部,负责生产调节新陈代谢的激素。甲状腺癌的发病率在全球范围内呈上升趋势,但其死亡率保持相对稳定,这可能与早期诊断和治疗技术的进步有关。
甲状腺癌的预后受多种因素影响,包括病理类型、治疗效果和患者的整体健康状况。乳头状癌是最常见的类型,通常预后较好,而未分化癌和甲状腺髓样癌的预后较差。
甲状腺癌传统的治疗手段包括手术、放射性碘治疗和甲状腺素替代治疗。对于晚期或难治性甲状腺癌,近年来分子靶向治疗和免疫治疗的研究取得了显著进展。
- 分子靶向治疗:分子靶向治疗通过抑制肿瘤生长和扩散的特定分子通路来治疗癌症。例如,索拉非尼是第一个被FDA批准用于治疗进展性放射性碘难治性分化型甲状腺癌(RR-DTC)的分子靶向药物。此外,RET抑制剂塞尔帕替尼在治疗RET突变型甲状腺髓样癌(MTC)中表现出显著的疗效。
- 免疫治疗:免疫治疗通过激活或增强患者的免疫系统来攻击肿瘤细胞。虽然目前关于GLP-1RAs和DPP-4i药物的使用与甲状腺癌风险之间的关系仍存在争议,但免疫检查点抑制剂等免疫治疗方法在甲状腺癌治疗中正受到关注。
甲状腺癌药物靶点
甲状腺癌药物靶点相关产品推荐
● 靶点蛋白
CSB-MP619964HU1
Measured by its binding ability in a functional ELISA. Immobilized PD-1 at 2 μg/ml can bind Anti-PD-1 recombinant antibody, the EC50 of human PD-1 protein is 6.087-7.854 ng/ml.
CSB-MP007763HU
Measured by its binding ability in a functional ELISA. Immobilized HER2 at 2 μg/ml can bind Trastuzumab, the EC50 is 2.179-2.825 ng/ml.
CSB-MP733578HU
Measured by its binding ability in a functional ELISA. Immobilized CD276 at 2 μg/ml can bind Anti-CD276 rabbit monoclonal antibody, the EC50 of human CD276 protein is 1.961-2.243 ng/ml.
CSB-MP005165HU
Measured by its binding ability in a functional ELISA. Immobilized Human CEACAM5 at 2μg/mL can bind Anti-CEACAM5 recombinant antibody (CSB-RA005165MA1HU), the EC50 is 0.8955-1.719 ng/mL.
CSB-MP006163HU1
Measured by its binding ability in a functional ELISA. Immobilized CD152 at 2 μg/ml can bind Anti-CD152 rabbit monoclonal antibody (CSB-RA213310A0HU), the EC50 of human CD152 protein is 27.14-34.82 ng/ml.
CSB-MP882142HU
Measured by its binding ability in a functional ELISA. Immobilized DLL3 at 2 μg/ml can bind Anti-DLL3 Recombinant Antibody(CSB-RA882142A1HU), the EC50 is 1.102-1.707 ng/mL.
CSB-MP007765HU
Measured by its binding ability in a functional ELISA. Immobilized NRG1 (CSB-MP016077HU1(F6)) at 2 μg/ml can bind human ERBB3, the EC50 is 12.32-15.74 ng/ml.
CSB-MP878942HU1
Measured by its binding ability in a functional ELISA. Immobilized PD-L1 at 2 μg/ml can bind Anti- PD-L1 mouse monoclonal antibody(CSB-MA878942A1m, antigen from E.coli), the EC50 of human PD-L1 protein is 1.252-1.653 ng/mL
● 稳定细胞株
HEK293F/Human DLL3 Stable Cell Line
CSB-SC007681HU
Untransfected HEK293 cells (green line) and transfected Human DLL3 HEK293 stable cells (red line) were stained with anti-DLL3 antibody (rovalpituzumab-like) (2µg/1*106 cells), washed and then followed by FITC-conjugated anti-Human IgG1 Fc antibody and analyzed with flow cytometry.
● 重组抗体
CSB-RA005165MA3HU
Overlay Peak curve showing Hela cells surface stained with CSB-RA005165MA3HU (red line) at 1:100.
CSB-RA006163MA1HU
Overlay Peak curve showing JK cells surface stained with CSB-RA006163MA1HU (red line) at 1:50.
CSB-RA882142A1HU
Untransfected HEK293 cells surface (green line) and transfected Human DLL3 HEK293 stable cells surface (red line) were stained with anti-DLL3 antibody (rovalpituzumab-like) (2µl/1*106 cells).
CSB-RA007717MA1HU
Overlay Peak curve showing MCF7 cells surface stained with CSB-RA007717MA1HU (red line) at 1:100.
产品名称 | 货号 | 靶点 | 反应种属 | 应用范围 |
---|---|---|---|---|
CD274 Recombinant Monoclonal Antibody | CSB-RA977797A0HU | CD274 | Human | ELISA, WB, IHC |
CD274 Recombinant Monoclonal Antibody | CSB-RA878942MA1HU | CD274 | Human | ELISA, IHC, FC |
CD3E Recombinant Monoclonal Antibody | CSB-RA004931MA1HU | CD3E | Human | ELISA, FC |
CEACAM1 Recombinant Monoclonal Antibody | CSB-RA147192A0HU | CEACAM1 | Human | ELISA, IHC |
CEACAM5 Recombinant Monoclonal Antibody | CSB-RA005165MA3HU | CEACAM5 | Human | ELISA, IF, FC |
CEACAM5 Recombinant Monoclonal Antibody | CSB-RA005165MA1HU | CEACAM5 | Human | ELISA |
CTLA4 Recombinant Monoclonal Antibody | CSB-RA213310A0HU | CTLA4 | Human | ELISA, IHC |
CTLA4 Recombinant Monoclonal Antibody | CSB-RA006163MA1HU | CTLA4 | Human, Mouse | ELISA, WB, IF, FC |
DLL3 Recombinant Monoclonal Antibody | CSB-RA882142A1HU | DLL3 | Human | ELISA, FC |
EPCAM Recombinant Monoclonal Antibody | CSB-RA932207A0HU | EPCAM | Human | ELISA, WB |
EPCAM Recombinant Monoclonal Antibody | CSB-RA439934A0HU | EPCAM | Human | ELISA, WB, IHC |
EPCAM Recombinant Monoclonal Antibody | CSB-RA007717MA1HU | EPCAM | Human | ELISA, IHC, FC |
ERBB2 Recombinant Monoclonal Antibody | CSB-RA260392A0HU | ERBB2 | Human | ELISA, IHC, IF |
ERBB2 Recombinant Monoclonal Antibody | CSB-RA007763MA1HU | ERBB2 | Human | ELISA |
Phospho-ERBB2 (Y1139) Recombinant Monoclonal Antibody | CSB-RA588766A0HU | ERBB2 | Human | ELISA, IHC, IF |
ERBB2 Recombinant Monoclonal Antibody | CSB-RA007763MA2HU | ERBB2 | Human | ELISA, IHC |
ERBB3 Recombinant Monoclonal Antibody | CSB-RA937008A0HU | ERBB3 | Human | ELISA, IF |
FAS Recombinant Monoclonal Antibody | CSB-RA252392A0HU | FAS | Human | ELISA, WB, IHC |
ICAM1 Recombinant Monoclonal Antibody | CSB-RA162789A0HU | ICAM1 | Human | ELISA, IHC, FC |
IGF1R Recombinant Monoclonal Antibody | CSB-RA011087MA1HU | IGF1R | Human | ELISA, FC |
PDCD1 Recombinant Monoclonal Antibody | CSB-RA240597A0HU | PDCD1 | Human | ELISA, WB, IHC |
PGF Recombinant Monoclonal Antibody | CSB-RA280380A0HU | PGF | Human | ELISA, IHC |
TOP1 Recombinant Monoclonal Antibody | CSB-RA792129A0HU | TOP1 | Human | ELISA, WB, IHC, FC, IP |